Stifel Downgrades Sarepta Therapeutic (SRPT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Baird Downgrades Sarepta Therapeutic (SRPT) to Neutral
October 28, 2014 6:46 AM EDTBaird downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Neutral with a price target of $21.00 (from $53.00).
Analyst Brian Skorney said, "Sarepta's regulatory update casts uncertainty around both the timeline for eteplirsen NDA submission and the fundamental underpinning of the drug's mechanism: dystrophin... More
Sarepta's (SRPT) New Timeline Might be Unrealistic, Says Deutsche Bank
October 27, 2014 12:51 PM EDTDeutsche Bank maintained a Hold rating on Sarepta Therapeutic (NASDAQ: SRPT) and reduced its price target to $24.00 (from $35.00). Earlier Sarepta announced the FDA requires additional data as part of the NDA submission for Eteplirsen, which will delay its NDA filing for Etepliersen to mid-2015. Analyst Robyn Karnauskas said the company's timeline was aggressive and potentially unrealistic.
"Today, the company seemed surprised with the FDAs addl requirements published in the minutes from a meeting in Sept. We note that these minutes nor the minutes from April have been made public, so we... More
JMP Securities Downgrades Sarepta Therapeutic (SRPT) to Market Perform
October 27, 2014 11:41 AM EDTJMP Securities downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $23.56 yesterday.
... MoreSarepta Therapeutic (SRPT) Story Remains Intact, Needham & Company Says
October 27, 2014 10:07 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying while the NDA filing delay is an unfortunate setback the story remains intact.
Merrer said, "In its latest vacillation, the FDA is now requesting 3 month data... More
Sarepta Therapeutics (SRPT) Reports More Data Needed for Eteplirsen NDA Submission
October 27, 2014 7:05 AM EDTSarepta Therapeutics (NASDAQ: SRPT) provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).
In meeting minutes received last week from a Type B Pre-NDA meeting that took place in September 2014, the FDA provided updated guidance regarding the specific data to be included as part of, or at the time of, Sareptas NDA submission. The guidance states that additional data are now required as part of... More
